Prevalence of vertebral fractures independent of BMD and anticancer treatment in patients with testicular germ cell tumors

Journal of Clinical Endocrinology and Metabolism

Volumn 95, Issue 11, 2010, Pages 4933-4942

  Willemse, P M ^a   Hamdy, N A T ^a   Van Wulften, L ^a   Van Steijn van Tol, A Q M J ^a   Putter, H ^a   Osanto, S ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; DACTINOMYCIN; DEXAMETHASONE; ESTRADIOL; FOLLITROPIN; LUTEINIZING HORMONE; TESTOSTERONE; VITAMIN D;

ADULT; AGE DISTRIBUTION; ARTICLE; BONE DENSITY; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVOR; CONTROLLED STUDY; CORRELATION ANALYSIS; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; ESTRADIOL BLOOD LEVEL; FOLLITROPIN BLOOD LEVEL; GERM CELL TUMOR; GONAD; HUMAN; HYPOGONADISM; LUTEINIZING HORMONE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; ORCHIECTOMY; OSTEOPENIA; OSTEOPOROSIS; PREVALENCE; PRIORITY JOURNAL; SINGLE DRUG DOSE; SPINE RADIOGRAPHY; TESTOSTERONE BLOOD LEVEL; THORACOLUMBAR SPINE; TUMOR CLASSIFICATION; VERTEBRA FRACTURE; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY;

EID: 78049517581     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2010-0093     Document Type: Article

References (41)

1. de Wit R, Roberts JT, Wilkinson PM, de Mulder PH, Mead GM, Fosså SD, Cook P, de Prijck L, Stenning S, Collette L 2001 Equivalence of three or four cycles of bleomycin, etoposide, and cisplatin chemotherapy and of a 3- or 5-day schedule in good-prognosis germ cell cancer: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council. J Clin Oncol 19:1629-1640 (Pubitemid 32230862)
2. Einhorn LH, Donohue J 1977 Cis-diamminedichloroplatinum, vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer. Ann Intern Med 87:293-298
3. Saxman SB, Finch D, Gonin R, Einhorn LH 1998 Long-term follow-up of a phase III study of three versus four cycles of bleomycin, etoposide, and cisplatin in favorable-prognosis germ-cell tumors: the Indian University experience. J Clin Oncol 16:702-706
4. Brown JE, Ellis SP, Silcocks P, Blumsohn A, Gutcher SA, Radstone C, Hancock BW, Hatton MQ, Coleman RE 2006 Effect of chemotherapy on skeletal health in male survivors from testicular cancer and lymphoma. Clin Cancer Res 12:6480-6486
5. Morley JE, Patrick P, Perry 3rd HM 2002 Evaluation of assays available to measure free testosterone. Metabolism 51:554-559 (Pubitemid 34516507)
6. Vermeulen A, Verdonck L, Kaufman JM 1999 A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab 84:3666-3672
7. Holick MF 2007 Vitamin D deficiency. N Engl J Med 357:266-281
8. Roux C, Bischoff-Ferrari HA, Papapoulos SE, de Papp AE, West JA, Bouillon R 2008 New insights into the role of vitamin D and calcium in osteoporosis management: an expert roundtable discussion. Curr Med Res Opin 24:1363-1370
9. Lackner JE, Märk I, Schatzl G, Marberger M, Kratzik C 2007 Hypogonadism and androgen deficiency symptoms in testicular cancer survivors. Urology 69:754-758
10. Looker AC, Wahner HW, Dunn WL, Calvo MS, Harris TB, Heyse SP, Johnston Jr CC, Lindsay RL 1995 Proximal femur bone mineral levels of US adults. Osteoporos Int 5:389-409
11. World Health Organization 1994 Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Tech Rep Ser 843. Geneva: World Health Organization
12. Stutz JA, Barry BP, Maslanka W, Sokal M, Green DJ, Pearson D 1998 Bone density: is it affected by orchidectomy and radiotherapy given for stage I seminoma of the testis? Clin Oncol 10:44-49
13. Genant HK, Wu CY, van Kuijk C, Nevitt MC 1993 Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 8:1137-1148 (Pubitemid 23261108)
14. Delmas PD, Genant HK, Crans GG, Stock JL, Wong M, Siris E, Adachi JD 2003 Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: results from the MORE trial. Bone 33:522-532
15. Black DM, Palermo L, Nevitt MC, Genant HK, Epstein R, San Valentin R, Cummings SR 1995 Comparison of methods for defining prevalent vertebral deformities: the Study of Osteoporotic Fractures. J Bone Miner Res 10:890-902
16. Burger H, van Daele PL, Algra D, Hofman A, Grobbee DE, Schütte HE, Birkenhäger JC, Pols HA 1994 Vertebral deformities as predictors of non-vertebral fractures. BMJ 309:991-992
17. Hasserius R, Karlsson MK, Nilsson BE, Redlund-Johnell I, Johnell O 2003 Prevalent vertebral deformities predict increased mortality and increased fracture rate in both men and women: a 10-year population-based study of 598 individuals from the Swedish cohort in the European Vertebral Osteoporosis Study. Osteoporos Int 14:61-68
18. Pongchaiyakul C, Nguyen ND, Jones G, Center JR, Eisman JA, Nguyen TV 2005 Asymptomatic vertebral deformity as a major risk factor for subsequent fractures and mortality: a long-term prospective study. J Bone Miner Res 20:1349-1355 (Pubitemid 41033519)
19. Wainwright SA, Marshall LM, Ensrud KE, Cauley JA, Black DM, Hillier TA, Hochberg MC, Vogt MT, Orwoll ES 2005 Hip fracture in women without osteoporosis. J Clin Endocrinol Metab 90:2787-2793
20. Ferrar L, Jiang G, Cawthon PM, San Valentin R, Fullman R, Lambert L, Cummings SR, Black DM, Orwoll E, Barrett-Connor E, Ensrud K, Fink HA, Eastell R 2007 Identification of vertebral fracture and non-osteoporotic short vertebral height in men: the MrOS study. J Bone Miner Res 22:1434-1441
21. Van Staa TP, Laan RF, Barton IP, Cohen S, Reid DM, Cooper C 2003 Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy. Arthritis Rheum 48:3224-3229
22. Brennemann W, Stoffel-Wagner B, Helmers A, Mezger J, Jäger N, Klingmüller D 1997 Gonadal function of patients treated with cisplatin based chemotherapy for germ cell cancer. J Urol 158:844-850 (Pubitemid 127739756)
23. Petersen PM, Giwercman A, Skakkebaek NE, Rørth M 1998 Gonadal function in men with testicular cancer. Semin Oncol 25:224-233
24. Nord C, Bjøro T, Ellingsen D, Mykletun A, Dahl O, Klepp O, Bremnes RM, Wist E, Fosså SD 2003 Gonadal hormones in long-term survivors 10 years after treatment for unilateral testicular cancer. Eur Urol 44:322-328
25. Kreuser ED, Harsch U, Hetzel WD, Schreml W 1986 Chronic gonadal toxicity in patients with testicular cancer after chemotherapy. Eur J Cancer Clin Oncol 22:289-294
26. Palmieri G, Lotrecchiano G, Ricci G, Spiezia R, Lombardi G, Bianco AR, Torino G 1996 Gonadal function after multimodality treatment in men with testicular germ cell cancer. Eur J Endocrinol 134:431-436 (Pubitemid 26155504)
27. van Casteren NJ, Boellaard WP, Romijn JC, Dohle GR 2010 Gonadal dysfunction in male cancer patients before cytotoxic treatment. Int J Androl 33:73-79
28. Iqbal J, Sun L, Kumar TR, Blair HC, Zaidi M 2006 Follicle-stimulating hormone stimulates TNF production from immune cells to enhance osteoblast and osteoclast formation. Proc Natl Acad Sci USA 103:14925-14930
29. Sun L, Peng Y, Sharrow AC, Iqbal J, Zhang Z, Papachristou DJ, Zaidi S, Zhu LL, Yaroslavskiy BB, Zhou H, Zallone A, Sairam MR, Kumar TR, Bo W, Braun J, Cardoso-Landa L, Schaffler MB, Moonga BS, Blair HC, Zaidi M 2006 FSH directly regulates bone mass. Cell 125:247-260
30. Baron R 2006 FSH versus estrogen: who's guilty of breaking bones? Cell Metab 3:302-305
31. Williams GR 2007 Hypogonadal bone loss: sex steroids or gonadotropins? Endocrinology 148:2610-2612
32. Skakkebaek NE, Rajpert-De Meyts E, Main KM 2001 Testicular dysgenesis syndrome: an increasingly common developmental disorder with environmental aspects. Hum Reprod 16:972-978 (Pubitemid 32451837)
33. Hoei-Hansen CE, Holm M, Rajpert-De Meyts E, Skakkebaek NE 2003 Histological evidence of testicular dysgenesis in contralateral biopsies from 218 patients with testicular germ cell cancer. J Pathol 200:370-374 (Pubitemid 36827311)
34. Richiardi L, Akre O 2005 Fertility among brothers of patients with testicular cancer. Cancer Epidemiol Biomarkers Prev 14:2557-2562
35. Ismail AA, O'Neill TW, Cooper C, Silman AJ 2000 Risk factors for vertebral deformities in men: relationship to number of vertebral deformities. European Vertebral Osteoporosis Study Group. J Bone Miner Res 15:278-283
36. Lunt M, Felsenberg D, Reeve J, Benevolenskaya L, Cannata J, Dequeker J, Dodenhof C, Falch JA, Masaryk P, Pols HA, Poor G, Reid DM, Scheidt-Nave C, Weber K, Varlow J, Kanis JA, O'Neill TW, Silman AJ 1997 Bone density variation and its effects on risk of vertebral deformity in men and women studied in thirteen European centers: the EVOS Study. J Bone Miner Res 12:1883-1894
37. Lunt M, O'Neill TW, Felsenberg D, Reeve J, Kanis JA, Cooper C, Silman AJ 2003 Characteristics of a prevalent vertebral deformity predict subsequent vertebral fracture: results from the European Prospective Osteoporosis Study (EPOS). Bone 33:505-513 (Pubitemid 37222376)
38. McCloskey EV, Spector TD, Eyres KS, Fern ED, O'Rourke N, Vasikaran S, Kanis JA 1993 The assessment of vertebral deformity: a method for use in population studies and clinical trials. Osteoporos Int 3:138-147
39. Pluijm SM, Tromp AM, Smit JH, Deeg DJ, Lips P 2000 Consequences of vertebral deformities in older men and women. J Bone Miner Res 15:1564-1572 (Pubitemid 30484526)
40. Samelson EJ, Hannan MT, Zhang Y, Genant HK, Felson DT, Kiel DP 2006 Incidence and risk factors for vertebral fracture in women and men: 25-year follow-up results from the population-based Framingham study. J Bone Miner Res 21:1207-1214
41. Szulc P, Munoz F, Marchand F, Delmas PD 2001 Semiquantitative evaluation of prevalent vertebral deformities in men and their relationship with osteoporosis: the MINOS study. Osteoporos Int 12:302-310